-
Innovation Ranking
NewInnovation Ranking – Curis Inc
Curis Inc (Curis) is a biotechnology company that focuses on developing and commercializing novel drug candidates for treating cancers with substantial unmet medical need. The company’s lead product Erivedge has been developed in collaboration with F. Hoffmann-La Roche Ltd and Genentech, which is commercialized for the treatment of advanced basal cell carcinoma (BCC). The product is approved for use in patients with advanced BCC in the US, European Union (EU), Australia and several other countries. The company has four drug...
-
Product Insights
NewNet Present Value Model: Curis Inc’s Onvatilimab
Empower your strategies with our Net Present Value Model: Curis Inc's Onvatilimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Curis Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Curis Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
Net Present Value Model: Curis Inc’s Emavusertib Hydrochloride
Empower your strategies with our Net Present Value Model: Curis Inc's Emavusertib Hydrochloride report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMT-151 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMT-151 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMT-151 in Triple-Negative Breast Cancer (TNBC) Drug Details: AMT-151 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sabatolimab in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sabatolimab in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sabatolimab in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Emavusertib Hydrochloride in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Emavusertib Hydrochloride in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Emavusertib Hydrochloride in Gastric Cancer Drug Details: Emavusertib hydrochloride is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Emavusertib Hydrochloride in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Emavusertib Hydrochloride in Esophageal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Emavusertib Hydrochloride in Esophageal Cancer Drug Details: Emavusertib hydrochloride is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Emavusertib Hydrochloride in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Emavusertib Hydrochloride in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Emavusertib Hydrochloride in Adenocarcinoma Of The Gastroesophageal Junction...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brexanolone in Sleep Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brexanolone in Sleep Disorders report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brexanolone in Sleep Disorders Drug Details: Brexanolone is under development for...